Alvotech Reports Positive PK Data for Entyvio Biosimilar
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
FAIRFAX, Va., January 22, 2026 — Re:Cognition Health announced that Medicare coverage is now available for FDA-approved amyloid-targeting therapies...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
REYKJAVÍK, Iceland; LONDON, United Kingdom — December 22, 2025 — Alvotech has announced the European launch of the world’s...
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
